Product Type |
Peptides |
CAS |
2022956-48-3 |
Sequence(1LC) |
MEVGWYRSPFSRVVHLYRNGK-NH2 |
Sequence(3LC) |
Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-NH2 |
Synonyms |
MOG (35-55), amide(mouse,rat);MOG (35-55),amide |
Molecular Formula |
C118H178N36O28S1 |
Molecular Weight |
2581 |
Purity |
≥95% |
Appearance |
Lyophilized powder |
Solubility |
H2O:≥100 mg/mL; *Ultrasonic solubilization; |
Salt Form |
Trifluoroacetate salt |
Source |
Synthetic |
Storage |
Store at -20℃,2 years.(Avoid freeze/thaw cycles) |
Category/Label |
Other Peptides |
Background |
MOG peptide (35-55) is highly encephalitogenic and can induce strong T and B cell responses. A single injection of this peptide produces a relapsing-remitting neurologic disease with extensive plaque-like demyelination. Because of the clinical, histopathologic, and immunologic similarities with multiple sclerosis (MS), this MOG-induced demyelinating encephalomyelitis may serve as a model for investigating MS. |
In Vitro |
The expanded CD4+ T?cells are largely specific for the myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide 35-55 (MOG35-55), while clonally expanded CD8+ T?cells were non-responsive to myelin peptides or proteins. |
In Vivo |
MOG(35-55) amide, mouse, rat (3 mg/mL for 0.1 mL; s.c.; single dose) results active induction of experimental autoimmune encephalomyelitis (EAE) in mice. MOG(35-55) amide, mouse, rat (200 μg; s.c.; single dose) induces a increasing concentration of the eosinophil chemoattractant eotaxin-1 in the spinal cord in the course of EAE induced in C57BL/6 mice. |
Reference |
[1] F.Puentes et al., J. Neuroinflammation, 10, 118(2013). |
Unit |
Bottle |
Validity Period |
#N/A# |
Specification |
1mg 5mg |